Eribulin in Cancer Treatment
Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic b...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-08-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1660-3397/13/8/5016 |
| _version_ | 1811183919060484096 |
|---|---|
| author | Umang Swami Umang Shah Sanjay Goel |
| author_facet | Umang Swami Umang Shah Sanjay Goel |
| author_sort | Umang Swami |
| collection | DOAJ |
| description | Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials. |
| first_indexed | 2024-04-11T13:04:56Z |
| format | Article |
| id | doaj.art-4cddaf4658a34fea993b91de9f743a77 |
| institution | Directory Open Access Journal |
| issn | 1660-3397 |
| language | English |
| last_indexed | 2024-04-11T13:04:56Z |
| publishDate | 2015-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj.art-4cddaf4658a34fea993b91de9f743a772022-12-22T04:22:49ZengMDPI AGMarine Drugs1660-33972015-08-011385016505810.3390/md13085016md13085016Eribulin in Cancer TreatmentUmang Swami0Umang Shah1Sanjay Goel2University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USADepartment of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USADepartment of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USAHalichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.http://www.mdpi.com/1660-3397/13/8/5016breast cancerEMBRACEeribulinE7389Halichondrin BHalaven™microtubule inhibitorNSC 707389 |
| spellingShingle | Umang Swami Umang Shah Sanjay Goel Eribulin in Cancer Treatment Marine Drugs breast cancer EMBRACE eribulin E7389 Halichondrin B Halaven™ microtubule inhibitor NSC 707389 |
| title | Eribulin in Cancer Treatment |
| title_full | Eribulin in Cancer Treatment |
| title_fullStr | Eribulin in Cancer Treatment |
| title_full_unstemmed | Eribulin in Cancer Treatment |
| title_short | Eribulin in Cancer Treatment |
| title_sort | eribulin in cancer treatment |
| topic | breast cancer EMBRACE eribulin E7389 Halichondrin B Halaven™ microtubule inhibitor NSC 707389 |
| url | http://www.mdpi.com/1660-3397/13/8/5016 |
| work_keys_str_mv | AT umangswami eribulinincancertreatment AT umangshah eribulinincancertreatment AT sanjaygoel eribulinincancertreatment |